Logo image
Back
Use of methenamine hippurate to prevent urinary tract infections in community adult women: a systematic review and meta-analysis
Journal article   Open access   Peer reviewed

Use of methenamine hippurate to prevent urinary tract infections in community adult women: a systematic review and meta-analysis

Mina Bakhit, Natalia Krzyzaniak, Joanne Hilder, Justin Clark, Anna Mae Scott and Chris Del Mar
British journal of general practice, Vol.71(708), pp.E528-E537
07/2021
DOI: https://doi.org/10.3399/BJGP.2020.0833
PMID: 34001538
pdf
Use of methenamine hippurate to prevent urinary tract infections186.90 kBDownloadView
Published (Version of record)CC BY V4.0,  Open Access
url
Use of methenamine hippurate to prevent urinary tract infectionsView
Published (Version of record)CC BY V4.0,  Open

Related links

Metrics

24 Record Views
22 Times Cited - Web of Science

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Abstract

antibiotics methenamine hippurate primary care systematic review urinary tract infections
Background: Urinary tract infections (UTIs) are often treated with antibiotics and are a source of antibiotic overuse. Aim: To systematically review randomised controlled trials (RCTs) of adult women in the community with a history of recurrent UTIs and who use methenamine hippurate prophylactically. Design and setting: Systematic review of women in the UK, Australia, Norway, and US (aged >= 18 years) with recurrent UTIs receiving methenamine hippurate against placebo or no treatment, and antibiotics. Method: The authors searched three databases, clinical trial registries, and performed forward-backward citation analysis on references of included studies. Results: Six studies involving 557 participants were included (447 were analysed). Of the six studies, five were published and one was an unpublished trial record with results, three compared methenamine hippurate against placebo or control, and three compared methenamine hippurate with antibiotics. For the number of patients who remained asymptomatic, methenamine hippurate showed a non-statistically significant trend of benefit versus antibiotics over 12 months (risk ratio [RR] 0.65, 95% confidence interval [CI] = 0.40 to 1.07, I-2 49%), versus control over 6 or 12 months (RR 0.56, 95% CI = 0.13 to 2.35, I-2 93%), and a non-statistically significant trend versus any antibiotic for abacteruria (RR 0.80, 95% CI = 0.62 to 1.03, I-2 23%). A similar non-statistically significant trend of benefits for methenamine hippurate for the number of UTI or bacteriuric episodes was found, and a non-statistically significant difference in the number of patients experiencing adverse events between methenamine hippurate and any comparator, with a trend towards benefit for the methenamine hippurate, was identified. Antibiotic use and resistance were not consistently reported. Conclusion: There is insufficient evidence to be certain of the benefits of methenamine hippurate to prevent UTI. Further research is needed to test the drug's effectiveness in preventing UTIs and as an alternative for antibiotic treatment for UTI.

Details

Logo image